Investor Event

ShareSoc Webinar with Faron Pharmaceuticals (FARN)
3 November 2020

Markku Jalkanen, CEO

Company: Faron Pharmaceuticals (FARN)
 3rd November 2020
Time: 5pm start – 6pm finish
Presenter: Markku Jalkanen, CEO
Format: Webinar

Company Information: Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development and is currently in phase I/II. Traumakine, the Company’s pipeline candidate to prevent vascular leakage and organ failures is currently being tested in several Phase III studies around the world against COVID-19. Traumakine is intravenous IFN beta-1a, which is a strong anti-viral and anti-inflammatory agent. Faron is based in Turku, Finland. Further information is available at


This is a 3 step process:
1) Log in to your ShareSoc account or Join ShareSoc for free
2) Click ‘Submit’ on the form below
3) Click on the link on the next page to register with GoToWebinar to COMPLETE THE REGISTRATION

Once you have registered fully with GoToWebinar you will receive an email notification, as well as reminders 1 day and 1 hour before the event starts.

Add to calendar
Event Details:
  • Event: ShareSoc Webinar with Faron Pharmaceuticals (FARN) - 3 November 2020
  • Date: 03/11/2020
  • Time: Presentation Starts at 5pm
  • Location: Webinar
Add to calendar
Event Details:
  • Event ShareSoc Webinar with Faron Pharmaceuticals (FARN) - 3 November 2020
  • Date 03/11/2020
  • Time Presentation Starts at 5pm
  • Location Webinar
  • Description Presenter:
    Markku Jalkanen, CEO